Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, APYX MEDICAL CORPORATION reported revenue of $53M, up 9.9% year over year. Operating margin was -12.2% and net margin -21.2%, on a free-cash-flow margin of -17.2% with capital expenditure at 2.1% of revenue. Every figure is computed directly from APYX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $53M | -12.2% | -21.2% |
| FY2024 | $48M | -39.2% | -48.8% |
| FY2023 | $52M | -33.0% | -35.7% |
| FY2022 | $45M | -52.9% | -52.1% |
| FY2021 | $49M | -29.8% | -31.3% |
How does APYX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.